世界の次世代乳がん診断・スクリーニング市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Next-Generation Breast Cancer Diagnostic and Screening Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12507 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、次世代乳がん診断・スクリーニングのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。次世代乳がん診断・スクリーニングの種類別市場規模（リアルタイムPCR（q-PCR）、免疫組織化学（IHC）、次世代シーケンシング（NGS）、蛍光in-situハイブリダイゼーション（FISH））、用途別市場規模（院内感染研究所、がん研究所、診断センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・次世代乳がん診断・スクリーニングの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Abbott Laboratories、Agendia、Agilent Technologies、Ambry Genetics、Biocept、Biotheranostics、Centogene、Danaher Corporation、EXACT Sciences Corporation、Roche Holding AG、Fulgent Genetics、Illumina、Invitae、Lucence Diagnostics Pte Ltd、Myriad Genetics ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：リアルタイムPCR（q-PCR）、免疫組織化学（IHC）、次世代シーケンシング（NGS）、蛍光in-situハイブリダイゼーション（FISH） ・用途別分析2016年-2026年：院内感染研究所、がん研究所、診断センター ・次世代乳がん診断・スクリーニングの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・次世代乳がん診断・スクリーニングのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・次世代乳がん診断・スクリーニングのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・次世代乳がん診断・スクリーニングの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・次世代乳がん診断・スクリーニングの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Next-Generation Breast Cancer Diagnostic and Screening market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Next-Generation Breast Cancer Diagnostic and Screening size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Next-Generation Breast Cancer Diagnostic and Screening market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Next-Generation Breast Cancer Diagnostic and Screening market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Real-Time PCR (q-PCR)
Immunohistochemistry (IHC)
Next-Generation Sequencing (NGS)
Fluorescent In-Situ Hybridization (FISH)

Market segment by Application, can be divided into
Hospital-associated Labs
Cancer Research Institutes
Diagnostic Centers

Market segment by players, this report covers
Abbott Laboratories
Agendia
Agilent Technologies
Ambry Genetics
Biocept
Biotheranostics
Centogene
Danaher Corporation
EXACT Sciences Corporation
Roche Holding AG
Fulgent Genetics
Illumina
Invitae
Lucence Diagnostics Pte Ltd
Myriad Genetics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Next-Generation Breast Cancer Diagnostic and Screening product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Next-Generation Breast Cancer Diagnostic and Screening, with revenue, gross margin and global market share of Next-Generation Breast Cancer Diagnostic and Screening from 2019 to 2021.
Chapter 3, the Next-Generation Breast Cancer Diagnostic and Screening competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Next-Generation Breast Cancer Diagnostic and Screening market forecast, by regions, technology and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Next-Generation Breast Cancer Diagnostic and Screening research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Next-Generation Breast Cancer Diagnostic and Screening
1.2 Classification of Next-Generation Breast Cancer Diagnostic and Screening by Technology
1.2.1 Overview: Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Type in 2020
1.2.3 Real-Time PCR (q-PCR)
1.2.4 Immunohistochemistry (IHC)
1.2.5 Next-Generation Sequencing (NGS)
1.2.6 Fluorescent In-Situ Hybridization (FISH)
1.3 Global Next-Generation Breast Cancer Diagnostic and Screening Market by Application
1.3.1 Overview: Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital-associated Labs
1.3.3 Cancer Research Institutes
1.3.4 Diagnostic Centers
1.4 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size & Forecast
1.5 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast by Region
1.5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region, (2016-2021)
1.5.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2016-2026)
1.5.4 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2016-2026)
1.5.6 South America Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
1.6.2 Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
1.6.3 Next-Generation Breast Cancer Diagnostic and Screening Trends Analysis
2 Company Profiles
2.1 Abbott Laboratories
2.1.1 Abbott Laboratories Details
2.1.2 Abbott Laboratories Major Business
2.1.3 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.1.4 Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Abbott Laboratories Recent Developments and Future Plans
2.2 Agendia
2.2.1 Agendia Details
2.2.2 Agendia Major Business
2.2.3 Agendia Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.2.4 Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Agendia Recent Developments and Future Plans
2.3 Agilent Technologies
2.3.1 Agilent Technologies Details
2.3.2 Agilent Technologies Major Business
2.3.3 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.3.4 Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Agilent Technologies Recent Developments and Future Plans
2.4 Ambry Genetics
2.4.1 Ambry Genetics Details
2.4.2 Ambry Genetics Major Business
2.4.3 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.4.4 Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Ambry Genetics Recent Developments and Future Plans
2.5 Biocept
2.5.1 Biocept Details
2.5.2 Biocept Major Business
2.5.3 Biocept Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.5.4 Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Biocept Recent Developments and Future Plans
2.6 Biotheranostics
2.6.1 Biotheranostics Details
2.6.2 Biotheranostics Major Business
2.6.3 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.6.4 Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Biotheranostics Recent Developments and Future Plans
2.7 Centogene
2.7.1 Centogene Details
2.7.2 Centogene Major Business
2.7.3 Centogene Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.7.4 Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Centogene Recent Developments and Future Plans
2.8 Danaher Corporation
2.8.1 Danaher Corporation Details
2.8.2 Danaher Corporation Major Business
2.8.3 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.8.4 Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Danaher Corporation Recent Developments and Future Plans
2.9 EXACT Sciences Corporation
2.9.1 EXACT Sciences Corporation Details
2.9.2 EXACT Sciences Corporation Major Business
2.9.3 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.9.4 EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 EXACT Sciences Corporation Recent Developments and Future Plans
2.10 Roche Holding AG
2.10.1 Roche Holding AG Details
2.10.2 Roche Holding AG Major Business
2.10.3 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.10.4 Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Roche Holding AG Recent Developments and Future Plans
2.11 Fulgent Genetics
2.11.1 Fulgent Genetics Details
2.11.2 Fulgent Genetics Major Business
2.11.3 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.11.4 Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Fulgent Genetics Recent Developments and Future Plans
2.12 Illumina
2.12.1 Illumina Details
2.12.2 Illumina Major Business
2.12.3 Illumina Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.12.4 Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Illumina Recent Developments and Future Plans
2.13 Invitae
2.13.1 Invitae Details
2.13.2 Invitae Major Business
2.13.3 Invitae Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.13.4 Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Invitae Recent Developments and Future Plans
2.14 Lucence Diagnostics Pte Ltd
2.14.1 Lucence Diagnostics Pte Ltd Details
2.14.2 Lucence Diagnostics Pte Ltd Major Business
2.14.3 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.14.4 Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Lucence Diagnostics Pte Ltd Recent Developments and Future Plans
2.15 Myriad Genetics
2.15.1 Myriad Genetics Details
2.15.2 Myriad Genetics Major Business
2.15.3 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
2.15.4 Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Myriad Genetics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Next-Generation Breast Cancer Diagnostic and Screening Players Market Share
3.2.2 Top 10 Next-Generation Breast Cancer Diagnostic and Screening Players Market Share
3.2.3 Market Competition Trend
3.3 Next-Generation Breast Cancer Diagnostic and Screening Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue and Market Share by Type (2016-2021)
4.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application (2016-2021)
5.2 Next-Generation Breast Cancer Diagnostic and Screening Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2026)
6.2 North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2026)
6.3 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
6.3.1 North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2026)
6.3.2 United States Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
6.3.3 Canada Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
6.3.4 Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2026)
7.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2026)
7.3 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
7.3.1 Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2026)
7.3.2 Germany Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
7.3.3 France Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
7.3.5 Russia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
7.3.6 Italy Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2026)
8.2 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2026)
8.3 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size by Region
8.3.1 Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Region (2016-2026)
8.3.2 China Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
8.3.3 Japan Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
8.3.4 South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
8.3.5 India Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
8.3.7 Australia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2026)
9.2 South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2026)
9.3 South America Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
9.3.1 South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2026)
9.3.2 Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
9.3.3 Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2026)
10.2 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2026)
10.3 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Market Size by Country
10.3.1 Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2026)
10.3.2 Turkey Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
10.3.4 UAE Next-Generation Breast Cancer Diagnostic and Screening Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Next-Generation Breast Cancer Diagnostic and Screening Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) by Region (2016-2021)
Table 5. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Region (2021-2026)
Table 6. Abbott Laboratories Corporate Information, Head Office, and Major Competitors
Table 7. Abbott Laboratories Major Business
Table 8. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 9. Abbott Laboratories Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Agendia Corporate Information, Head Office, and Major Competitors
Table 11. Agendia Major Business
Table 12. Agendia Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 13. Agendia Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Agilent Technologies Corporate Information, Head Office, and Major Competitors
Table 15. Agilent Technologies Major Business
Table 16. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 17. Agilent Technologies Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Ambry Genetics Corporate Information, Head Office, and Major Competitors
Table 19. Ambry Genetics Major Business
Table 20. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 21. Ambry Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Biocept Corporate Information, Head Office, and Major Competitors
Table 23. Biocept Major Business
Table 24. Biocept Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 25. Biocept Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Biotheranostics Corporate Information, Head Office, and Major Competitors
Table 27. Biotheranostics Major Business
Table 28. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 29. Biotheranostics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Centogene Corporate Information, Head Office, and Major Competitors
Table 31. Centogene Major Business
Table 32. Centogene Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 33. Centogene Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Danaher Corporation Corporate Information, Head Office, and Major Competitors
Table 35. Danaher Corporation Major Business
Table 36. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 37. Danaher Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. EXACT Sciences Corporation Corporate Information, Head Office, and Major Competitors
Table 39. EXACT Sciences Corporation Major Business
Table 40. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 41. EXACT Sciences Corporation Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Roche Holding AG Corporate Information, Head Office, and Major Competitors
Table 43. Roche Holding AG Major Business
Table 44. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 45. Roche Holding AG Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Fulgent Genetics Corporate Information, Head Office, and Major Competitors
Table 47. Fulgent Genetics Major Business
Table 48. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 49. Fulgent Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Illumina Corporate Information, Head Office, and Major Competitors
Table 51. Illumina Major Business
Table 52. Illumina Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 53. Illumina Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Invitae Corporate Information, Head Office, and Major Competitors
Table 55. Invitae Major Business
Table 56. Invitae Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 57. Invitae Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Lucence Diagnostics Pte Ltd Corporate Information, Head Office, and Major Competitors
Table 59. Lucence Diagnostics Pte Ltd Major Business
Table 60. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 61. Lucence Diagnostics Pte Ltd Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Myriad Genetics Corporate Information, Head Office, and Major Competitors
Table 63. Myriad Genetics Major Business
Table 64. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Product and Solutions
Table 65. Myriad Genetics Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) by Players (2019-2021)
Table 67. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Players (2019-2021)
Table 68. Breakdown of Next-Generation Breast Cancer Diagnostic and Screening by Company Type (Tier 1, Tier 2 and Tier 3)
Table 69. Next-Generation Breast Cancer Diagnostic and Screening Players Head Office, Products and Services Provided
Table 70. Next-Generation Breast Cancer Diagnostic and Screening Mergers & Acquisitions in the Past Five Years
Table 71. Next-Generation Breast Cancer Diagnostic and Screening New Entrants and Expansion Plans
Table 72. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) by Type (2016-2021)
Table 73. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Type (2016-2021)
Table 74. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Forecast by Type (2021-2026)
Table 75. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2021)
Table 76. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Forecast by Application (2021-2026)
Table 77. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2021) & (USD Million)
Table 78. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2021-2026) & (USD Million)
Table 79. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2021) & (USD Million)
Table 80. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2021-2026) & (USD Million)
Table 81. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2021) & (USD Million)
Table 82. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2021-2026) & (USD Million)
Table 83. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2021) & (USD Million)
Table 84. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2021-2026) & (USD Million)
Table 85. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2021) & (USD Million)
Table 86. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2021-2026) & (USD Million)
Table 87. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2021) & (USD Million)
Table 88. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2021-2026) & (USD Million)
Table 89. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2021) & (USD Million)
Table 90. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2021-2026) & (USD Million)
Table 91. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2021) & (USD Million)
Table 92. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2021-2026) & (USD Million)
Table 93. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Region (2016-2021) & (USD Million)
Table 94. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue by Region (2021-2026) & (USD Million)
Table 95. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2021) & (USD Million)
Table 96. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2021-2026) & (USD Million)
Table 97. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2021) & (USD Million)
Table 98. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2021-2026) & (USD Million)
Table 99. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2021) & (USD Million)
Table 100. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2021-2026) & (USD Million)
Table 101. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2016-2021) & (USD Million)
Table 102. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Type (2021-2026) & (USD Million)
Table 103. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2016-2021) & (USD Million)
Table 104. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Application (2021-2026) & (USD Million)
Table 105. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2016-2021) & (USD Million)
Table 106. Middle East & Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Next-Generation Breast Cancer Diagnostic and Screening Picture
Figure 2. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Technology in 2020
Figure 3. Real-Time PCR (q-PCR)
Figure 4. Immunohistochemistry (IHC)
Figure 5. Next-Generation Sequencing (NGS)
Figure 6. Fluorescent In-Situ Hybridization (FISH)
Figure 7. Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Application in 2020
Figure 8. Hospital-associated Labs Picture
Figure 9. Cancer Research Institutes Picture
Figure 10. Diagnostic Centers Picture
Figure 11. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Region (2016-2026)
Figure 14. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Region in 2020
Figure 15. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Next-Generation Breast Cancer Diagnostic and Screening Market Drivers
Figure 21. Next-Generation Breast Cancer Diagnostic and Screening Market Restraints
Figure 22. Next-Generation Breast Cancer Diagnostic and Screening Market Trends
Figure 23. Abbott Laboratories Recent Developments and Future Plans
Figure 24. Agendia Recent Developments and Future Plans
Figure 25. Agilent Technologies Recent Developments and Future Plans
Figure 26. Ambry Genetics Recent Developments and Future Plans
Figure 27. Biocept Recent Developments and Future Plans
Figure 28. Biotheranostics Recent Developments and Future Plans
Figure 29. Centogene Recent Developments and Future Plans
Figure 30. Danaher Corporation Recent Developments and Future Plans
Figure 31. EXACT Sciences Corporation Recent Developments and Future Plans
Figure 32. Roche Holding AG Recent Developments and Future Plans
Figure 33. Fulgent Genetics Recent Developments and Future Plans
Figure 34. Illumina Recent Developments and Future Plans
Figure 35. Invitae Recent Developments and Future Plans
Figure 36. Lucence Diagnostics Pte Ltd Recent Developments and Future Plans
Figure 37. Myriad Genetics Recent Developments and Future Plans
Figure 38. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Players in 2020
Figure 39. Next-Generation Breast Cancer Diagnostic and Screening Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 40. Global Top 3 Players Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share in 2020
Figure 41. Global Top 10 Players Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share in 2020
Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 43. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Type in 2020
Figure 44. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share Forecast by Type (2021-2026)
Figure 45. Global Next-Generation Breast Cancer Diagnostic and Screening Revenue Share by Application in 2020
Figure 46. Global Next-Generation Breast Cancer Diagnostic and Screening Market Share Forecast by Application (2021-2026)
Figure 47. North America Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Type (2016-2026)
Figure 48. North America Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Application (2016-2026)
Figure 49. North America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Country (2016-2026)
Figure 50. United States Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Canada Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Mexico Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Europe Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Type (2016-2026)
Figure 54. Europe Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Application (2016-2026)
Figure 55. Europe Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Country (2016-2026)
Figure 56. Germany Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. France Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Russia Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Italy Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Type (2016-2026)
Figure 62. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Region (2016-2026)
Figure 64. China Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Japan Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South Korea Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. India Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Southeast Asia Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Australia Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. South America Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Type (2016-2026)
Figure 71. South America Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Application (2016-2026)
Figure 72. South America Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Country (2016-2026)
Figure 73. Brazil Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Argentina Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Type (2016-2026)
Figure 76. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Sales Market Share by Application (2016-2026)
Figure 77. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Revenue Market Share by Country (2016-2026)
Figure 78. Turkey Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. UAE Next-Generation Breast Cancer Diagnostic and Screening Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Methodology
Figure 82. Research Process and Data Source

---